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.1. Need for developing case deﬁnitions and guidelines for data
ollection, analysis, and presentation for non-reassuring fetal
tatus as an adverse event following immunization
Non-reassuring fetal status is a term used to describe suspected
etal hypoxia and is meant to replace the more ubiquitous term
fetal distress.” Fetal distress, deﬁned as progressive fetal hypoxia
nd/or acidemia secondary to inadequate fetal oxygenation, is a
erm that is used to indicate changes in fetal heart patterns, reduced
etal movement, fetal growth restriction, and presence of meco-
ium stained ﬂuid [1]. Although fetal distress may  be associated
∗ Corresponding author. Tel.: +1 919 681 5220.
E-mail address: contact@brightoncollaboration.org (C. Gravett).
1 Brighton Collaboration homepage: http://www.brightoncollaboration.org.
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.043
264-410X/© 2016 Published by Elsevier Ltd. This is an open access article under the CC Bwith neonatal encephalopathy, the generic term has poor predic-
tive value for neonatal outcomes; most neonates will be vigorous
and healthy at birth despite a diagnosis of fetal distress. Fetal dis-
tress can only be observed indirectly, usually via electronic fetal
heart rate monitoring which is subject to high intra- and inter-
observer variability in data interpretation [2–4]. For this reason,
many experts recommend abandoning the term fetal distress, and
adopting the term non-reassuring fetal status to describe clinical
interpretation of fetal well-being [1,5,6]. Consistent with current
opinion in the ﬁeld, we recommend use of the term non-reassuring
fetal status for use in monitoring fetal response following
immunization.
Non-reassuring fetal status is not an adverse event per se,
but rather an indicator of an underlying condition resulting in
temporary or permanent oxygen deprivation to the fetus which
may  lead to fetal hypoxia and metabolic acidosis. Since fetal
oxygenation is dependent upon maternal oxygenation and pla-
cental perfusion, perturbations of maternal oxygenation, uterine
Y license (http://creativecommons.org/licenses/by/4.0/).
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lood supply, placental transfer or fetal gas transport may  lead
o fetal hypoxia and non-reassuring fetal status [7]. Conditions
ommonly associated with non-reassuring fetal status include
aternal cardiovascular disease, anemia, diabetes, hypertension,
nfection, placental abruption, abnormal presentation of the fetus,
ntrauterine growth restriction and umbilical cord compression,
mong other obstetric, maternal or fetal conditions.
The fetus experiences three stages of deterioration when oxygen
evels are depleted: transient hypoxia without metabolic acido-
is, tissue hypoxia with a risk of metabolic acidosis, and hypoxia
ith metabolic acidosis [7,8]. Fetal response to oxygen depriva-
ion is regulated by the autonomous nervous system, mediated
y parasympathetic and sympathetic mechanisms. The fetus is
quipped with compensatory mechanisms for transient hypoxia
uring labor, but prolonged, uninterrupted fetal hypoxia may
ead progressively to acidosis with cell death, tissue damage,
rgan failure and potentially death. In response to hypoxia, fetal
ompensatory mechanisms include 1) a decrease in heart rate;
) a reduction in oxygen consumption secondary to cessation
f nonessential functions such as gross body movements; 3) a
edistribution of cardiac output to preferentially perfuse organs,
uch as the heart, brain, and adrenal glands; and 4) a switch
o anaerobic cellular metabolism [9]. Prolonged fetal hypoxia
s associated with signiﬁcant perinatal morbidity and mortality
ith particular concern for short- and long-term complications
ncluding encephalopathy, seizures, cerebral palsy, and neurode-
elopmental delay [10,11]. The fetal heart rate changes markedly
n response to prolonged oxygen deprivation, making fetal heart
ate monitoring a potentially valuable and commonly used tool for
ssessing fetal oxygenation status in real time. Non-reassuring fetal
eart rate patterns are observed in approximately 15% of labors
12].
The two most common methods of monitoring fetal heart
ate are cardiotocography (CTG) and intermittent auscultation.
n high resource settings, continuous electronic fetal heart rate
onitoring, via cardiotocography is the most prevalent method.
ontinuous CTG involves monitoring the fetal heart rate and uter-
ne contractility simultaneously to detect fetal heart rate patterns
ssociated with deﬁcient fetal oxygen supply [8]. Normal CTG trac-
ngs are characterized by 1) stable baseline fetal heart rate (FHR)
f 120–160 beats per minute (bpm), 2) FHR variability between 5
nd 25 bpm above and below baseline FHR, and 3) periodic changes
n the baseline FHR (accelerations above baseline or decelerations
elow baseline) [13]. While accelerations are associated with fetal
ell-being, decelerations, especially prolonged bradycardia, late
ecelerations, and severe variable decelerations are indicative of
etal stress and should prompt the clinician to evaluate and initi-
te intrauterine resuscitation with consideration for delivery of the
etus as indicated. Abnormal fetal heart rate patterns have high sen-
itivity, but low speciﬁcity and low predictive value to discriminate
etween neonates with or without metabolic acidosis [14]. While a
ormal fetal heart rate pattern is usually indicates reassuring fetal
tatus, an abnormal fetal heart rate pattern does not necessarily
quate with hypoxia or acidosis.
Although continuous CTG is the accepted standard of care in
ost high resource settings, use of continuous CTG in low resource
etting is not feasible or recommended [15]. Continuous CTG
equires costly equipment, expert maintenance, supply chain for
onsumables, and extensive training and high level of technical
kill to interpret tracings. Additionally, continuous CTG can lead
o higher rates of un-necessary interventions that may  pose addi-
ional risk to mothers in settings where safe cesarean delivery is
ot readily available [16].
In  settings where CTG is unavailable, intermittent auscultation is
ecommended for all laboring parturients [17]. Intermittent auscul-
ation (IA) involves assessing the fetal heart rate at predetermined 
intervals with either a fetal stethoscope, or handheld Doppler.
Abnormal heart rate ﬁndings by IA indicative of non-reassuring
fetal status include prolonged fetal tachycardia or bradycardia,
presence of repetitive or prolonged decelerations, and uterine
tachysystole (more than 5 uterine contractions in a 10 min  period).
There is no evidence that IA performs worse than CTG in reduc-
ing morbidity and mortality associated with fetal acidosis. Studies
comparing CTG to IA show no reduction in the risk of perinatal death
or cerebral palsy [16,18]. Intermittent auscultation, characterized
by low cost and low technology equipment, is more feasible than
CTG in low resource settings. However, it requires a high level of
training and skill, frequent interaction between patient and health
care provider, and does not provide as sophisticated a level of infor-
mation that may  be needed in high risk populations.
Several efforts to develop standards for deﬁning non-reassuring
fetal status have been made in response to confusion in recog-
nizing and managing fetal heart rate patterns indicative of fetal
compromise. The most widely accepted standards for classifying
non-reassuring fetal heart rates come from the National Institute
of Child Health and Human Development (NICHD) in the United
States and The International Federation of Gynecology and Obstet-
rics (FIGO) (Table 1). In 1997, NICHD convened a workshop with
the express purpose of developing “a standardized and rigorously,
unambiguously described set of deﬁnitions to quantitate fetal heart
monitoring [19]. The workshop produced standardized nomencla-
ture for characterizing fetal heart rate patterns, which was  widely
adopted by western obstetric societies. In 2008, a follow-up work-
shop including the Society for Maternal Fetal Medicine and the
American College of Obstetricians and Gynecologists was con-
vened, resulting in the development of a three-tiered classiﬁcation
system of fetal heart rate patterns to guide management of fetal
compromise [20,21]. The Working Group uses these guidelines as
a basis for the highest level of certainty for deﬁning a case of non-
reassuring fetal status. The NICHD guidelines are limited in deﬁning
fetal status in all settings as they are only intended for use with CTG.
A second important set of guidelines, more applicable to all sett-
ings was  ﬁrst introduced by FIGO in 1986 and was  updated in 2015
[17,22–26]. The FIGO guidelines are the only guidelines with broad
international consensus, and are simpliﬁed, with less emphasis on
decelerations compared to the NICHD guidelines when evaluating
CTG tracings. FIGO also provides recommendations for evaluat-
ing and categorizing fetal heart rate via intermittent auscultation,
making these guidelines more useful for low resource settings.
When CTG is not available, the Working Group recommends incor-
porating heart rate patterns from IA into the case deﬁnition for
non-reassuring fetal status.
Little  is known about the relationships among non-reassuring
fetal status and maternal immunization, especially in LMIC where
fetal assessment may  not be routine. There are few publications
reporting on fetal status following immunization; those that do are
case reports or small series that have frequently not used stan-
dardized deﬁnitions [27–29]. Possible reasons that immunization
surveillance has failed to report on cases of non-reassuring fetal
status include the fact that a causal relationship is rarely if ever
established, the low predictive value of non-reassuring fetal status
to predict adverse neonatal outcomes, the difﬁculty of temporally
associating vaccination with fetal status, as the two events are likely
to be monitored at very different time-points in pregnancy, the
failure to include fetal status as an outcome variable in immuniza-
tion trials or surveillance. Estimates of the incidence of fetal status
following maternal immunization have been hampered by limited
data and lack of standard case deﬁnitions.
34 (2016) 6084–6092 6085Moving forward, uniform and standardized deﬁnitions for non-
reassuring fetal status and fetal well-being will be critical in
immunization trials surveillance and monitoring to insure data
comparability across trials. This is imperative to facilitate data
Table  1
Comparison of NICHD and FIGO guidelines for interpretation of fetal heart rate via continuous cardiotocography. FHR = fetal heart rate, bpm = beats per minute.
NICHD three-tier fetal heart rate interpretation system (2008) FIGO consensus guidelines on intrapartum fetal monitoring CTG tracing
classiﬁcations (2015)
FHR designation Description FHR designation Description
Category I tracing Baseline heart rate:
110–160 bpm
Variability:
Moderate
Decelerations:
No late decelerations
Early decelerations may  be present or absent
Accelerations may  be present or absent
Normal Baseline heart rate:
110–160 bpm
Variability:
5–25 bpm
Decelerations:
No repetitive decelerations
Category II tracing FHR tracing does not meet criteria for category I
or category III
Suspicious Lacking at least one characteristic of normality,
but with no pathologic features
Category III tracing 1) Variability:
Absent FHR baseline variability
AND any of the following:
Recurrent late decelerations
Recurrent variable decelerations
Bradycardia (FHR < 110 bpm)
OR
2) Sinusoidal pattern
Pathological Baseline heart rate:
<100 bpm
Variability:
Reduced variability for >15 min
Increased variability for >30 min
OR
Sinusoidal pattern for >30 min
Decelerations:
Repetitive late or prolonged decelerations during
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C. Gravett et al. / Vaccine 34 (2016) 6084–60926086nterpretation and promote the scientiﬁc understanding of the
vent.
.2. Methods for the development of the case deﬁnition and
uidelines for data collection, analysis, and presentation for
on-reassuring fetal status as an adverse events following
mmunization
Following the process described in the overview paper as
ell as on the Brighton Collaboration Website http://www.
rightoncollaboration.org/internet/en/index/process.html, the
righton Collaboration Fetal Distress Working Group was  formed in
015 and included members of clinical and academic, as well as
ublic health background. Members have experience in high and
ow resources settings. The composition of the working and refer-
nce group as well as results of the web-based survey completed
y the reference group with subsequent discussions in the working
roup can be viewed at: http://www.brightoncollaboration.org/
nternet/en/index/working groups.html.
To guide the decision-making for the case deﬁnition and guide-
ines, literature was searched using Medline, Embase and the
ochrane Libraries, including the terms vaccines, vaccination, or
mmunization (or terms beginning with vaccin-, immuni-, inocular-
 and non-reassuring fetal status, fetal distress, intrapartum fetal
sphyxia, non-reassuring fetal heart rate, fetal compromise, fetal
ypoxia, fetal intolerance of labor. To identify case deﬁnitions and
easures of fetal distress in all settings, the above search terms
ere also searched with the terms developing country or low
esource setting.  The search was limited to publications written in
nglish with human subjects. The search resulted in the identiﬁ-
ation of 105 references. All abstracts were screened for possible
eports of non-reassuring fetal status, or fetal distress, following
mmunization. Eighteen articles with potentially relevant material
ere reviewed in more detail, in order to identify studies using case
eﬁnitions or, in their absence, providing clinical descriptions of
he case material. This resulted in a detailed summary of 2 articles,
ncluding information on the study type, the vaccine, the diag-
ostic criteria or case deﬁnition put forth, the time interval since
mmunization, and other symptoms. Multiple general medical and
bstetric text books and obstetric society publications were also
earched.>30 min  or 20 min if reduced variability
OR
One prolonged deceleration with >5 min
Most publications were single case reports. The terminology and
case deﬁnitions were inconsistent among studies, with very few
reporting case deﬁnitions at all. An inventory comprising 5 relevant
case deﬁnitions of non-reassuring fetal status was made available
to working group members.
1.3. Rationale for selected decisions about the case deﬁnition of
non-reassuring fetal status as an adverse event following
immunization
1.3.1. The term non-reassuring fetal status
Several related terms are commonly used to describe fetal
status including “fetal distress”, “birth asphyxia”, and “fetal intol-
erance to labor”. The Working Group was  initially tasked with
developing a case deﬁnition for “fetal distress”, but for reasons
previously discussed, this term was abandoned and replaced with
“non-reassuring fetal status”. The Working Group chose not to use
the term “fetal intolerance of labor” because specifying such a nar-
row timeframe fails to capture non-reassuring fetal status in the
antepartum period prior to the onset of labor.
In developing a case deﬁnition for non-reassuring fetal status,
the Working Group included only cases for which fetal heart rate
can be ascertained. The inability to measure fetal heart rate does
not permit a diagnosis of non-reassuring fetal status at any accept-
able level of diagnostic certainty. Within the deﬁnition context,
however, the three diagnostic levels must not be misunderstood as
reﬂecting different grades of clinical severity. They instead reﬂect
diagnostic certainty (see below). All Levels are considered accept-
able depending on the availability of diagnostic tools in each site.
1.3.2. The term “birth asphyxia”
Birth asphyxia is often erroneously used interchangeably with
fetal distress. Birth asphyxia is deﬁned as the failure of the
neonate to start regular respiration within one minute of birth,
resulting from progressive hypoxia leading to acidosis in utero.
Non-reassuring fetal status is distinct from birth asphyxia, as non-
reassuring fetal status may  be detected via fetal heart monitoring
as a response to fetal hypoxia long before acidosis or asyphxia
occur and will not necessarily result in birth asphyxia [5]. There-
fore, although non-reassuring fetal status may  be observed prior to
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ccine irth asphyxia, the Working Group did not include this term in the
eveloping the case deﬁnition.
.3.3. Formulating a case deﬁnition that reﬂects diagnostic
ertainty: weighing speciﬁcity versus sensitivity
As detection of non-reassuring fetal status is dependent on the
ype of technology used, and variable interpretation of fetal heart
ate tracings, the evidence documenting fetal status may  vary con-
iderably. The case deﬁnition has been formulated such that the
evel I deﬁnition is maximally speciﬁc for the condition, and relies
n the highest level of evidence and technology available to detect
he event. Two  additional diagnostic levels have been included
n the deﬁnition, offering a stepwise decrease in technological
equirements, in an attempt to be inclusive of settings with less
ophisticated means of detecting fetal well-being. In this way, our
ntent is that all possible cases of non-reassuring fetal status in all
ettings can be captured.
Importantly, the grading of deﬁnition levels is based entirely
n diagnostic certainty, not clinical severity of an event. Thus, a
linically severe event may  appropriately be classiﬁed as Level Two
r Three rather than Level One if it could reasonably be due to non-
eassuring fetal status. Detailed information about the severity of
he event should additionally always be recorded, as speciﬁed by
he data collection guidelines.
.3.4. The meaning of “sudden onset” and “rapid progression” in
he context of non-reassuring fetal status
The term “sudden onset” refers to an event that occurred unex-
ectedly and without warning leading to a marked change in a
oman’s previously stable condition.
The term “rapid progression” is a conventional clinical term. An
xact time-frame should not be offered since this could refer to
 wide range of signs and symptoms without a scientiﬁc evidence
ase. Using an arbitrarily restrictive set point might bias future data
ollection unnecessarily.
.3.5. Rationale for individual criteria or decision made related to
he case deﬁnition
.3.5.1. Radiology ﬁndings. Doppler sonography utilizes ultrasound
o measure the change in frequency of energy wave transmis-
ion when relative motion occurs between the source and the
bserver. Doppler sonography is used for non-invasive assess-
ent of circulation in many clinical conditions. In obstetrics, fetal
mbilical artery (UA) doppler velocimetry provides a noninva-
ive measure of the fetoplacental hemodynamic state. Abnormal
A Doppler indices indirectly reﬂect impedance of downstream
irculation and have been associated with fetal hypoxia, fetal
cidosis, and adverse perinatal outcomes [30–33]. Randomized
rials integrating UA Doppler velocimetry into antepartum fetal
urveillance of high risk pregnancies have demonstrated efﬁcacy
n the setting of fetal growth restriction or preeclampsia [34]. In
ddition to UA Doppler, middle cerebral artery (MCA) Doppler is
sed in the setting of suspected fetal anemia. Obstetric Doppler
maging requires a high level of training and technical ultra-
ound equipment, is not usually performed during labor when
TG is the preferred and superior modality to assess fetal well-
eing, and is not suitable for low resource settings. For these
easons, the Working Group decided that Doppler sonography does
ot merit inclusion in the case deﬁnition of non-reassuring fetal
tatus.
.3.5.2. Laboratory ﬁndings.
C. Gravett et al. / Va1.3.5.2.1. Fetal blood sampling. Discontinuous fetal blood
ampling has been used to monitor fetal acid–base metabolism
n the intrapartum period, when fetal heart rate tracings are sug-
estive of hypoxic insult. Fetal blood sampling allows analysis of 
pH, lactate concentrations, partial pressure oxygen (pO2) and car-
bon dioxide (pCO2) from which base excess is calculated (BE). Fetal
blood pH less than or equal to 7.20, pO2 > 65 mmHg, and BE > −9.8,
and lactate >4.8 mmol/L indicate metabolic acidosis requiring inter-
vention to restore adequate oxygen supply to the fetus [26,35,36].
Fetal blood sampling is problematic in diagnosing non-reassuring
fetal status for several reasons. Fetal blood sampling is an inva-
sive and uncomfortable procedure, requiring ruptured membranes
and incision into the fetal scalp to sample blood, thus exposing the
fetus to risk of infection [37]. The procedure requires a high level
of training and technical laboratory equipment including real time
blood gas analysis [38]. Fetal blood sampling is seldom performed
in high resource settings and is not suitable for low resource sett-
ings. For these reasons, the Working Group concluded that fetal
blood sampling does not merit inclusion in the case deﬁnition of
non-reassuring fetal status.
1.3.5.2.2. Umbilical cord blood sampling. Immediately follow-
ing birth, metabolic acidosis in the fetus can be detected by
analyzing arterial and venous blood from the umbilical cord. Cord
blood analysis for pH, pCO2, and the derivative bicarbonate (HCO3)
and base deﬁcit (BD) values is highly recommended in all cases
of suspected fetal hypoxia/acidosis. Metabolic acidosis is deﬁned
as the measurement of the umbilical artery blood pH < 7.00 and
BD > 12 mmol/L [39]. The Working Group included cord blood anal-
ysis as part of the case deﬁnition for non-reassuring fetal status as
the only method to objectively ascertain the occurrence of fetal
hypoxia/acidosis immediately prior to birth. Recognizing that not
all settings will be equipped to perform cord blood analysis, the
working group did not include these criteria across all levels of
diagnostic certainty.
1.3.5.2.3. Pathology ﬁndings: autopsy. The term non-reassuring
fetal status does not have high positive predictive value for neonatal
morbidity and mortality. Furthermore, non-reassuring fetal status
does not produce pathognomonic post-mortem features. There-
fore, post-mortem ﬁndings are not included in the case deﬁnition
of non-reassuring fetal status.
1.3.5.2.4. Physical ﬁndings. The APGAR score is a standardized
assessment of the neonate’s physiological condition immediately
following birth, as well the neonatal response to resuscitation, if
required [40]. The APGAR score evaluates color, heart rate, reﬂexes,
muscle tone, and respiration. Low APGAR scores may  be observed
as a result of intrapartum fetal compromise. Fetal hypoxic insult
may  precede low APGAR scores when the hypoxic injury is sufﬁ-
cient to affect the pulmonary, neurologic or cardiovascular system
of the fetus, but APGAR scores alone are not sufﬁciently sensitive
or speciﬁc for diagnosing fetal hypoxia or acidosis and are only
weakly associated with non-reassuring fetal heart rate patterns.
There is a low correlation between low 1 and 5 min  APGAR scores
and metabolic acidosis [41,42], but many other conditions, includ-
ing neonatal sepsis, trauma, maternal drug use, fetal anomalies
and gestational age that may  contribute to low APGAR scores as
well, making causal inference problematic [8]. Furthermore, APGAR
scoring in not well standardized, and is inconsistently used in the
global setting. The Working Group did not include APGAR scores
as part of the case deﬁnition for non-reassuring status, but we do
recommend that 1, 5, and 10 min  APGAR scores be collected for
vaccine monitoring and surveillance purposes.
1.3.6. Inﬂuence of treatment on fulﬁllment of case deﬁnition
The Working Group decided against using “treatment” or “treat-
ment response” toward fulﬁllment of the non-reassuring fetal
status case deﬁnition. A treatment response or failure is not in
34 (2016) 6084–6092 6087itself diagnostic, and may  depend on variables such as clinical
status, time to treatment, and other clinical parameters. Treat-
ment strategies for non-reassuring fetal status are variable, ranging
from intrauterine resuscitation to performing cesarean section for
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ccine 6mmediate delivery of a compromised fetus. Treatment response
ill vary depending on the severity of fetal heart rate patterns, the
uration of altered heart rate, the clinician’s assessment of these
actors, and the resources available for intervention.
.3.7. Timing post immunization
Speciﬁc time frames for onset of symptoms following immu-
ization are not included for the following reasons:
Time from immunization was not included for deﬁning non-
eassuring fetal status because fetal status may  change at unknown
eriods in the ante- or intra-partum periods. Although we recog-
ize fetal status is most likely to be observed in the intrapartum
eriod when fetal heart rate monitoring is deployed, we did not
ant to narrow the time frame to the exclusion of fetal events
n the antepartum period. The Working Group does recommend
hat the time elapsed from vaccine administration to observation
f non-reassuring fetal status be recorded as a critical variable for
ata collection.
We  postulate that a deﬁnition designed to be a suitable tool for
esting causal relationships requires ascertainment of the outcome
e.g. non-reassuring fetal status) independent from the exposure
e.g. immunizations). Therefore, to avoid selection bias, a restric-
ive time interval from immunization to onset of non-reassuring
etal status should not be an integral part of such a deﬁnition.
nstead, where feasible, details of this interval should be assessed
nd reported as described in the data collection guidelines.
Further, non-reassuring fetal status often occurs outside the
ontrolled setting of a clinical trial or hospital. In some settings
etermining a clear timeline of the event may  be impossible, par-
icularly in less developed or rural settings. In order to avoid
electing against such cases, the Brighton Collaboration case deﬁ-
ition avoids setting arbitrary time frames.
.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview, the case deﬁnition is accompa-
ied by guidelines which are structured according to the steps of
onducting a clinical trial, i.e. data collection, analysis and presenta-
ion. Neither case deﬁnition nor guidelines are intended to guide or
stablish criteria for management of ill infants, children, or adults.
oth were developed to improve data comparability.
.5. Periodic review
Similar to all Brighton Collaboration case deﬁnitions and guide-
ines, review of the deﬁnition with its guidelines is planned on a
egular basis (i.e. every three to ﬁve years) or more often if needed.
. Case deﬁnition of non-reassuring fetal status
Level 1 of diagnostic certainty
Category III fetal heart rate tracings detected via continuous car-
diotocography as deﬁned by NICHD [20]
 Absent baseline fetal heart rate variability AND any of the follow-
ing:
- recurrent late decelerations
- recurrent variable deceleration
C. Gravett et al. / Va088- bradycardia (<110 bpm)
OR
 Sinusoidal pattern
AND
Umbilical cord blood analysis consistent with metabolic acidosis
(pH < 7.0 and Base deﬁcit >12 mmol/L)Level 2 of diagnostic certainty
• Category III fetal heart rate tracings detected via continuous car-
diotocography as deﬁned by NICHD [20]
◦ Absent baseline fetal heart rate variability AND any of the follow-
ing:
- recurrent late decelerations
- recurrent variable deceleration
- bradycardia (<110 bpm)
OR
◦ Sinusoidal pattern
Level 3 of diagnostic certainty
• Fetal heart pattern detected via intermittent auscultation sugges-
tive of fetal hypoxia [17]
◦ Baseline FHR <110 bpm or >160 bpm
◦ Presence of repetitive or prolonged (>3 min) decelerations
◦ More than 5 contractions in a 10 min  period
Major and minor criteria used in the case deﬁnition of non-
reassuring fetal status
Major criteria
Cardiovascular
CTG:
Category III heart
Rate tracing
• Absent baseline fetal heart rate variability AND any of the follow-
ing:
- recurrent late decelerations
- recurrent variable deceleration
- bradycardia < 110 beats/min
OR
• Sinusoidal pattern
IA:
Abnormal
Findings
• FHR <110 bpm OR >160 bpm
• Presence of repetitive or prolonged decelerations
• More than 5 contractions in a 10 min  period
Minor criteria
Laboratory
• Cord blood pH ≤7.0
• Cord blood base deﬁcit ≥12 mmol
3. Guidelines for data collection, analysis and presentation
of non-reassuring fetal status
The consensus of the Brighton Collaboration Non-Reassuring
Fetal Distress Working Group for non-reassuring fetal status was
to recommend the following guidelines to enable meaningful and
standardized collection, analysis, and presentation of information
about non-reassuring fetal status. However, implementation of all
guidelines might not be possible in all settings. The availability
of information may  vary depending upon resources, geographical
region, and whether the source of information is a prospective clin-
34 (2016) 6084–6092ical trial, a post-marketing surveillance or epidemiological study,
or an individual report of non-reassuring fetal status. Also, as
explained in more detail in the overview paper in this volume, these
guidelines have been developed by this working group for guidance
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• Values and units of routinely measured parameters (paper trac-
ings of EFM) (e.g. temperature, blood pressure) – in particular
those indicating the severity of the event;
3 The date and/or time of onset is deﬁned as the time post immunization, when
the ﬁrst sign or symptom indicative for non-reassuring fetal status occurred. This
ccine nly, and are not to be considered a mandatory requirement for data
ollection, analysis, or presentation.
.1. Data collection
These guidelines represent a desirable standard for the collec-
ion of data on availability following immunization to allow for
omparability of data, and are recommended as an addition to data
ollected for the speciﬁc study question and setting. The guidelines
re not intended to guide the primary reporting of non-reassuring
etal status to a surveillance system or study monitor. Investigators
eveloping a data collection tool based on these data collection
uidelines also need to refer to the criteria in the case deﬁnition,
hich are not repeated in these guidelines. The Brighton Col-
aboration has developed guidelines for data collection https://
rightoncollaboration.org/public/resources/standards/guidelines.
tml; and data collection forms https://brightoncollaboration.org/
ublic/resources/data-collection-forms.html.
Guidelines numbers below have been developed to address
ata elements for the collection of adverse event information as
peciﬁed in general drug safety guidelines by the International
onference on Harmonization of Technical Requirements for Reg-
stration of Pharmaceuticals for Human Use (43), and the form
or reporting of drug adverse events by the Council for Interna-
ional Organizations of Medical Sciences (44). These data elements
nclude an identiﬁable reporter and patient, one or more prior
mmunizations, and a detailed description of the adverse event,
n this case, of non-reassuring fetal status following immuniza-
ion. The additional guidelines have been developed as guidance for
he collection of additional information to allow for a more com-
rehensive understanding of non-reassuring fetal status following
mmunization.
.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
ollowing information should be recorded:
) Date of report.
) Name and contact information of person reporting2 and/or
diagnosing the non-reassuring fetal status as speciﬁed by
country-speciﬁc data protection law.
) Name and contact information of the investigator responsible
for the patient, as applicable.
) Relation to the patient (e.g., immunizer [clinician, nurse], family
member [indicate relationship], other).
.1.2. Vaccinee/Control
.1.2.1. Demographics. For all cases and/or all study participants,
s appropriate, the following information should be recorded:
) Case/study participant identiﬁers (e.g. ﬁrst name initial followed
by last name initial) or code (or in accordance with country-
speciﬁc data protection laws).
) Date of birth, age, and sex.
.1.2.2. Clinical and immunization history. For all cases and/or
ll study participants, as appropriate, the following information
hould be recorded:
C. Gravett et al. / Va) Past medical history, including hospitalizations, underlying
diseases/disorders, pre-immunization signs and symptoms
2 If the reporting center is different from the vaccinating center, appropriate and
imely communication of the adverse event should occur. 
including identiﬁcation of indicators for, or the absence of, a his-
tory of allergy to vaccines, vaccine components or medications;
food allergy; allergic rhinitis; eczema; asthma.
8) Any medication history (other than treatment for the event
described) prior to, during, and after immunization including
prescription and non-prescription medication as well as med-
ication or treatment with long half-life or long term effect.
(e.g. immunoglobulins, blood transfusion and immunosuppress-
ants).
9) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI)), in particular
occurrence of non-reassuring fetal status after a previous immu-
nization.
3.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
10) Date and time of immunization(s).
11) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL,  0.5 mL,  etc.), composition of any
diluent administered separately or added to the vaccine, and
number of dose if part of a series of immunizations against the
same disease).
12) The anatomical sites (including left or right side) of all immun-
izations (e.g. vaccine A in proximal left lateral thigh, vaccine B
in left deltoid).
13) Route and method of administration (e.g. intramuscular, intra-
dermal, subcutaneous, and needle-free (including type and
size), other injection devices).
14) Needle length and gauge.
3.1.4. The adverse event
15) For all cases at any level of diagnostic certainty and for reported
events with insufﬁcient evidence, the criteria fulﬁlled to meet
the case deﬁnition should be recorded.
Speciﬁcally document:
16) Clinical description of signs and symptoms of non-reassuring
fetal status, and if there was  medical conﬁrmation of the event
(i.e. patient seen by physician).
17) Date/time of onset,3 ﬁrst observation4 and diagnosis,5 end of
episode6 and ﬁnal outcome.7
18) Concurrent signs, symptoms, and diseases (e.g. maternal
conditions, known fetal conditions, abnormalities of labor,
abnormalities of delivery).
19) Time interval since immunization
20) Measurement/testing
34 (2016) 6084–6092 6089may  only be possible to determine in retrospect.
4 The date and/or time of ﬁrst observation of the ﬁrst sign or symptom indicative
for  non-reassuring fetal status can be used if date/time of onset is not known.
5 The date of diagnosis of an episode is the day post immunization when the event
met  the case deﬁnition at any level.
6 The end of an episode is deﬁned as the time the event no longer meets the case
deﬁnition at the lowest level of the deﬁnition.
7 E.g. recovery to pre-immunization health status, spontaneous resolution, ther-
apeutic intervention, persistence of the event, sequelae, death.
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34) The duration of a possible non-reassuring fetal status could be
analyzed as the interval between the date/time of onset1 of the
9 To determine the appropriate category, the user should ﬁrst establish, whether
a  reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of
the  deﬁnition is met, and there is evidence that the criteria of the next higher level
ccine 36Method of measurement (e.g. cardiotocograph, doppler, feto-
scope, etc. Include units of fetal heart trace (1 cm/min, etc.));
Results of laboratory examinations, surgical and/or pathological
ﬁndings and diagnoses if present (cord blood gases, pH)
APGARS at 1, 5, 10 min  for neonate
Occurrence of neonatal seizures
reatment given for non-reassuring fetal status, especially spec-
fy what and dosing.Outcome6 at last observation.Objective clinical
vidence supporting classiﬁcation of the event as “serious” 8 (e.g.
0 min  APGAR of 3 or less; presence of neonatal seizures, newborn
esuscitation required)Exposures other than the immunization
4 h before and after immunization (e.g. food, environmental,
lacental abruption, abdominal trauma) considered potentially rel-
vant to the reported event.Neonatal disposition
Gestational age
Birth weight
Birth outcome (e.g., live birth, stillbirth)
Delivery method (e.g. spontaneous vaginal, assisted vaginal,
cesarean section)
1, 5 and 10 min  APGAR scores
Presence of meconium
.1.5. Miscellaneous/General
6) The duration of surveillance for non-reassuring fetal status
should be predeﬁned based on
Biologic characteristics of the vaccine e.g. live attenuated versus
inactivated component vaccines;
Biologic characteristics of the vaccine-targeted disease;
Biologic characteristics of non-reassuring fetal heart rate includ-
ing patterns identiﬁed in previous trials (e.g. early-phase trials);
and
Biologic characteristics of the vaccinee (e.g. nutrition, underlying
disease like immunodepressing illness).
7) The duration of follow-up reported during the surveillance
period should be predeﬁned with continued follow-up to
resolution of the event. For non-reassuring fetal status, the
follow-up period should continue through the ante- and intra-
partum periods, as changes in fetal well-being can occur at any
point in pregnancy.
8) Methods of data collection should be consistent within and
between study groups, if applicable.
9) Follow-up of cases should attempt to verify and complete the
information collected as outlined in data collection guidelines
1–24.
0) Investigators of patients with non-reassuring fetal status
should provide guidance to reporters to optimize the quality
and completeness of information provided.
1) Reports of non-reassuring fetal status should be collected
throughout the study period regardless of the time elapsed
C. Gravett et al. / Va090between immunization and the adverse event. If this is not fea-
sible due to the study design, the study periods during which
safety data are being collected should be clearly deﬁned.
8 An AEFI is deﬁned as serious by international standards if it meets one or more of
he following criteria: 1) it results in death, 2) is life-threatening, 3) it requires inpa-
ient hospitalization or results in prolongation of existing hospitalization, 4) results
n  persistent or signiﬁcant disability/incapacity, 5) is a congenital anomaly/birth
efect, 6) is a medically important event or reaction.3.2. Data analysis
The following guidelines represent a desirable standard for anal-
ysis of data on non-reassuring fetal status to allow for comparability
of data, and are recommended as an addition to data analyzed for
the speciﬁc study question and setting.
32) Reported events should be classiﬁed in one of the following
ﬁve categories including the three levels of diagnostic cer-
tainty. Events that meet the case deﬁnition should be classiﬁed
according to the levels of diagnostic certainty as speciﬁed in
the case deﬁnition. Events that do not meet the case deﬁnition
should be classiﬁed in the additional categories for analysis.
Event classiﬁcation in 5 categories9
Event meets case deﬁnition
1) Level 1: Criteria as speciﬁed in the non-reassuring fetal status
case deﬁnition
2) Level 2: Criteria as speciﬁed in the non-reassuring fetal status
case deﬁnition
3) Level 3: Criteria as speciﬁed in the non-reassuring fetal status
case deﬁnition
Event does not meet case deﬁnition
Additional categories for analysis
4) Reported non-reassuring fetal status with insufﬁcient evidence
to meet the case deﬁnition10
5) Not a case of non-reassuring fetal status
33) The interval between immunization and reported non-
reassuring fetal status could be deﬁned as the date/time of
immunization to the date/time of onset2 of the ﬁrst symp-
toms and/or signs consistent with the deﬁnition. If few cases
are reported, the concrete time course could be analyzed for
each; for a large number of cases, data can be analyzed in the
following increments:
Subjects with non-reassuring fetal status by interval to pre-
sentation
Interval* Number
<1  h after immunization
1 h–<7 days after immunization
7  days–<30 days after immunization
>30 days–delivery after immunization
Total
4 (2016) 6084–6092of  diagnostic certainty are met, the event should be classiﬁed in the next category.
This approach should be continued until the highest level of diagnostic certainty
for a given event could be determined. Major criteria can be used to satisfy the
requirement of minor criteria. If the lowest level of the case deﬁnition is not met, it
should be ruled out that any of the higher levels of diagnostic certainty are met and
the  event should be classiﬁed in additional categories four or ﬁve.
10 If the evidence available for an event is insufﬁcient because information is miss-
ing,  such an event should be categorized as “Reported non-reassuring fetal status
with insufﬁcient evidence to meet the case deﬁnition”. An event does not meet the
case deﬁnition if investigation reveals a negative ﬁnding of a necessary criterion
(necessary condition) for diagnosis. Such an event should be rejected and classiﬁed
as  “Not a case of non-reassuring fetal status”.
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[3] Blackwell SC, Grobman WA,  Antoniewicz L, Hutchinson M,  Gyamﬁ Bannerman
C. Interobserver and intraobserver reliability of the NICHD 3-Tier Fetal Heart
Rate Interpretation System. Am J Obstet Gynecol 2011;205:e1–5, 378.
[4] Rhose S, Heinis AM,  Vandenbussche F, van Drongelen J, van Dillen J.
Inter- and intra-observer agreement of non-reassuring cardiotocography
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ﬁrst symptoms and/or signs consistent with the deﬁnition and
the end of episode5 and/or ﬁnal outcome.6 Whatever start and
ending are used, they should be used consistently within and
across study groups.
5) If more than one measurement of a particular criterion is taken
and recorded, the value corresponding to the greatest magni-
tude of the adverse experience could be used as the basis for
analysis. Analysis may  also include other characteristics like
qualitative patterns of criteria deﬁning the event.
6) The distribution of data (as numerator and denominator data)
could be analyzed in predeﬁned increments (e.g. measured
values, times), where applicable. Increments speciﬁed above
should be used. When only a small number of cases is pre-
sented, the respective values or time course can be presented
individually.
7) Data on non-reassuring fetal status obtained from subjects
receiving a vaccine should be compared with those obtained
from an appropriately selected and documented control
group(s) to assess background rates of hypersensitivity in non-
exposed populations, and should be analyzed by study arm and
dose where possible, e.g. in prospective clinical trials.
.3. Data presentation
These guidelines represent a desirable standard for the pre-
entation and publication of data on non-reassuring fetal status
ollowing immunization to allow for comparability of data, and
re recommended as an addition to data presented for the spe-
iﬁc study question and setting. Additionally, we recommended to
eferring to existing general guidelines for the presentation and
ublication of randomized controlled trials, systematic reviews,
nd meta-analyses of observational studies in epidemiology (e.g.
tatements of Consolidated Standards of Reporting Trials (CON-
ORT), of Improving the quality of reports of meta-analyses of
andomized controlled trials (QUORUM), and of Meta-analysis
f Observational Studies in Epidemiology (MOOSE), respectively)
45–47).
8) All reported events of non-reassuring fetal status should be
presented according to the categories listed in guideline 31
(verify numbers).
9) Data on possible non-reassuring fetal status events should be
presented in accordance with data collection guidelines 1–24
(verify numbers) and data analysis guidelines 31–36 (verify
numbers).
0) Terms to describe non-reassuring fetal status such as “low-
grade”, “mild”, “moderate”, “high”, “severe” or “signiﬁcant” are
highly subjective, prone to wide interpretation, and should be
avoided, unless clearly deﬁned.
1) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denomi-
ator data are usually not readily available, attempts should be
ade to identify approximate denominators. The source of the
enominator data should be reported and calculations of estimates
e described (e.g. manufacturer data like total doses distributed,
eporting through Ministry of Health, coverage/population based
ata, etc.).
C. Gravett et al. / Va2) The incidence of cases in the study population should be pre-
sented and clearly identiﬁed as such in the text.
3) If the distribution of data is skewed, median and range are usu-
ally the more appropriate statistical descriptors than a mean.However, the mean and standard deviation should also be pro-
vided.
44) Any publication of data on non-reassuring fetal status should
include a detailed description of the methods used for data
collection and analysis as possible. It is essential to specify:
• The study design;
• The method, frequency and duration of monitoring for non-
reassuring fetal status;
• The trial proﬁle, indicating participant ﬂow during a study includ-
ing drop-outs and withdrawals to indicate the size and nature of
the respective groups under investigation;
• The type of surveillance (e.g. passive or active surveillance);
• The characteristics of the surveillance system (e.g. population
served, mode of report solicitation);
• The search strategy in surveillance databases;
• Comparison group(s), if used for analysis;
• The instrument of data collection (e.g. standardized question-
naire, diary card, report form);
• Whether the day of immunization was  considered “day one” or
“day zero” in the analysis;
• Whether the date of onset2 and/or the date of ﬁrst observation3
and/or the date of diagnosis4 was used for analysis; and
• Use of this case deﬁnition for non-reassuring fetal status, in the
abstract or methods section of a publication.11
Disclaimer
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necessarily represent the views of their respective institutions.
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